Updated on 2025/03/06

写真a

 
KIMURA Tomokazu
 
Organization
Nagoya University Hospital Center for Postgraduate Clinical Training and Career Development Lecturer of hospital
Title
Lecturer of hospital
Contact information
メールアドレス
External link

Degree 2

  1. Doctor (Medicine) ( 2015.11   University of Tsukuba ) 

  2. Doctor of Medicine ( 2005.3   University of Tsukuba ) 

Research Interests 2

  1. Bladder Cancer

  2. 医学教育

Research Areas 1

  1. Life Science / Urology

Research History 3

  1. Nagoya University   Hospital   Clinical Lecture

    2024.1

  2. University of Tsukuba   Associate professor

    2023.4 - 2023.12

  3. University of Tsukuba   Lecturer

    2016.6 - 2023.3

Education 1

  1. University of Tsukuba

    1999.4 - 2005.3

Professional Memberships 1

  1. 日本泌尿器科学会

    2005.10

Committee Memberships 4

  1. 日本外科教育学会   評議員  

    2024.10   

      More details

    Committee type:Academic society

  2. 一般社団法人日本医学教育学会   医学教育専門家資格制度 TL・A・CDコース (タスクフォース)  

    2022.10   

  3. 公益社団法人医療系大学間共用試験実施評価機構   医学系OSCE課題作成委員会委員  

    2022.6   

  4. 日本泌尿器科学会   ダイバーシティー推進委員会 委員  

    2019.9 - 2025.5   

 

Papers 4

  1. Efficacy and safety of Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase II trial. International journal

    Tomokazu Kimura, Hitoshi Ishikawa, Yoshiyuki Nagumo, Yuta Sekino, Yukio Kageyama, Hiroki Ushijima, Taketo Kawai, Hideomi Yamashita, Haruhito Azuma, Keiji Nihei, Masae Takemura, Koichi Hashimoto, Kazushi Maruo, Toyonori Tsuzuki, Hiroyuki Nishiyama

    International journal of radiation oncology, biology, physics   Vol. 117 ( 3 ) page: 644 - 651   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To evaluate the safety and pathological complete response (pCR) rate of radiotherapy with atezolizumab as bladder-preserving therapy for invasive bladder cancer. PATIENTS AND METHODS: A multicenter, phase II study was conducted with clinically T2-3 or very high-risk T1 bladder cancer patients who were poor candidates for or refused radical cystectomy. Here, we report our interim analysis of pCR as a key secondary endpoint ahead of the progression-free survival rate primary endpoint. Radiotherapy (41.4 Gy to the small pelvic field and 16.2 Gy to the whole bladder) was given plus 1200 mg intravenous atezolizumab every 3 weeks. After 24 treatment weeks, response was assessed after transurethral resection and tumor programmed cell death ligand-1(PD-L1) expression was assessed using tumor-infiltrating immune cell scores. RESULTS: Forty-five patients enrolled from January 2019 to May 2021 were analyzed. The most common clinical T stage was T2 (73.3%), followed by T1 (15.6%) and T3 (11.1%). Most tumors were solitary (77.8%), small (<3 cm) (57.8%), and without concurrent carcinoma in situ (88.9%). Thirty-eight patients (84.4%) achieved pCR. High pCR rates were achieved in older patients (90.9%) and in patients with high PD-L1-expressing tumors (95.8% vs. 71.4%). Adverse events (AEs) occurred in 93.3% of patients, with diarrhea being the most common (55.6%), followed by frequent urination (42.2%) and dysuria (20.0%). The frequency of grade 3 AEs was 13.3% while no grade 4 AEs were observed. CONCLUSION: Combination therapy with radiotherapy and atezolizumab provides high pCR rates and acceptable toxicity, indicating it could be a promising option for bladder preservation therapy.

    DOI: 10.1016/j.ijrobp.2023.05.013

    Scopus

    PubMed

    CiNii Books

  2. Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif. International journal

    Tomokazu Kimura, Yukari Okita, Yoshiyuki Nagumo, Jas Min Chin, Muhammad Ali Fikry, Masanobu Shiga, Shuya Kandori, Takashi Kawahara, Hiroyuki Suzuki, Hiroyuki Nishiyama, Mitsuyasu Kato

    Pathology international   Vol. 74 ( 5 ) page: 262 - 273   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Bladder cancer is one of the most common cancers among men worldwide. Although multiple genomic mutations and epigenetic alterations have been identified, an efficacious molecularly targeted therapy has yet to be established. Therefore, a novel approach is anticipated. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type I transmembrane glycoprotein that is highly expressed in various cancers. In this study, we evaluated bladder cancer patient samples and found that GPNMB protein abundance is associated with high-grade tumors, and both univariate and multivariate analyses showed that GPNMB is a prognostic factor. Furthermore, the prognosis of patients with high GPNMB levels was significantly poorer in those with nonmuscle invasive bladder cancer (NMIBC) than in those with muscle invasive bladder cancer (MIBC). We then demonstrated that knockdown of GPNMB in MIBC cell lines with high GPNMB inhibits cellular migration and invasion, whereas overexpression of GPNMB further enhances cellular migration and invasion in MIBC cell lines with originally low GPNMB. Therefore, we propose that GPNMB is one of multiple driver molecules in the acquisition of cellular migratory and invasive potential in bladder cancers. Moreover, we revealed that the tyrosine residue in the hemi-immunoreceptor tyrosine-based activation motif (hemITAM) is required for GPNMB-induced cellular motility.

    DOI: 10.1111/pin.13419

    Scopus

    PubMed

  3. Adult genitourinary sarcoma: analysis using hospital-based cancer registry data in Japan. International journal

    Satoshi Nitta, Shuya Kandori, Kosuke Kojo, Shuhei Suzuki, Kazuki Hamada, Ichiro Chihara, Masanobu Shiga, Shotaro Sakka, Yoshiyuki Nagumo, Tomokazu Kimura, Bryan J Mathis, Hiromitsu Negoro, Ayako Okuyama, Takahiro Higashi, Hiroyuki Nishiyama

    BMC cancer   Vol. 24 ( 1 ) page: 215 - 215   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Genitourinary sarcomas are rare in adults and few large-scale studies on adult genitourinary sarcoma are reported. We aimed to elucidate the clinical characteristics, survival outcomes, and prognostic factors for overall survival of adult genitourinary sarcoma in Japan. METHODS: A hospital-based cancer registry data in Japan was used to identify and enroll patients diagnosed with genitourinary sarcoma in 2013. The datasets were registered from 121 institutions. RESULTS: A total of 116 men and 39 women were included, with a median age of 66 years. The most common primary site was the kidney in 47 patients, followed by the paratestis in 36 patients. The most common histological type was liposarcoma in 54 patients, followed by leiomyosarcoma in 25 patients. The 5-year overall survival rates were 57.6%. On univariate analysis, male gender, paratestis as primary organ, and histological subtype of liposarcoma were predictive of favorable survival while primary kidney, bladder, or prostate gland location were predictive of unfavorable survival. On multivariate analysis, primary paratestis was an independent predictor of favorable survival while primary kidney, bladder, or prostate gland were independent predictors of unfavorable survival. CONCLUSIONS: This is the first report showing the clinical characteristics and survival outcomes of adult genitourinary sarcoma in Japan using a real-world large cohort database.

    DOI: 10.1186/s12885-024-11952-0

    Scopus

    PubMed

  4. A new clustering model based on the seminal plasma/serum ratios of multiple trace element concentrations in male patients with subfertility.

    Takazo Tanaka, Kosuke Kojo, Yoshiyuki Nagumo, Atsushi Ikeda, Takuya Shimizu, Shunsuke Fujimoto, Toshiyuki Kakinuma, Masahiro Uchida, Tomokazu Kimura, Shuya Kandori, Hiromitsu Negoro, Hiroyuki Nishiyama

    Reproductive medicine and biology   Vol. 23 ( 1 ) page: e12584   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To investigate whether seminal plasma (SP)/serum ratios of multiple trace elements (TEs) can classify patients with male subfertility. METHODS: SP/serum ratios of 20 TEs (lithium, sodium, magnesium, phosphorus, sulfur, potassium, calcium, manganese, iron, cobalt, copper, zinc, arsenic, selenium, rubidium, strontium, molybdenum, cesium, barium, and thallium) were calculated for healthy volunteers (n = 4) and those consulting for male subfertility (n = 245). Volunteer semen samples were collected by split ejaculation into early and subsequent fractions, and SP/serum ratio data were compared between fractions. The patients' SP/serum ratio data were used in an unsupervised clustering analysis and qualitatively compared with the data from the fractions of ejaculation from the volunteers. Semen quality parameters and pregnancy outcomes were compared between patient clusters. RESULTS: The early fraction of volunteers was characterized by lower phosphorus and arsenic and 18 other higher TEs than the subsequent fraction. Cluster analysis classified patients into four distinct clusters, one sharing characteristics with the early fraction and another with the subsequent fraction. One cluster with the early fraction characteristics had significantly lower semen volume and higher pregnancy rates from spontaneous pregnancies or intrauterine insemination. CONCLUSIONS: Classification of patients based on SP/serum ratios of multiple TEs represents the dominance of fractions of ejaculation samples.

    DOI: 10.1002/rmb2.12584

    Scopus

    PubMed

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 膀胱がん微小環境におけるPLD1/2によるイムノメタボリズムの制御機構の解明

    Grant number:22K09466  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    神鳥 周也, 木村 友和, 西山 博之, 船越 祐司, 志賀 正宣

      More details

    Authorship:Coinvestigator(s) 

    膀胱がん微小環境におけるイムノメタボリズムを標的とするがん複合免疫療法開発の基盤を構築することを目的とし、PLDに着目して研究を行う。膀胱正所性モデルによるPLD1/PLD2-KOマウスの腫瘍形成能の比較を行い、その腫瘍組織のトランスクリプトーム解析を行う。トランスクリプトーム解析の結果に基づき、免疫細胞におけるPLDアイソザイム別の機能解析を行う。さらに、膀胱癌で臨床応用されているPD-1抗体とPLD阻害剤併用療法の抗腫瘍効果の評価することで、イムノメタボリズムを標的とするがん複合免疫療法の可能性を検討する。
    膀胱がん微小環境ががんの進展や治療奏効性に影響を及ぼす重要な因子であり、がん免疫療法に対する抵抗性獲得に寄与することが明らかとなってきた。本研究で着目するホスホリパーゼD(PLD)はホスファチジルコリンを加水分解して、ホスファチジン酸(PA)を産生するリン脂質代謝酵素であり、PAは脂質性シグナル伝達分子として多彩な生理機能を有している。予備実験としてPLD1/PLD2-KOマウスにおけるBBN膀胱発がん実験を行った。興味深いことに、PLD1-KOマウスでは発がんが抑制され、PLD2-KOマウスでは促進された。この結果から、膀胱がんにおいてPLD1とPLD2のがん免疫微小環境における役割が異なることが示唆された。そこで、PLDによるイムノメタボリズムに基づく、がん免疫微小環境への影響を明らかにし、新たながん複合免疫療法の開発への基盤を構築することを目的とした。
    マウス膀胱がん細胞株MB49による皮下移植モデルにおいても同様にPLD2-KOマウスでは腫瘍形成が促進された。BBN膀胱発がんモデルにおける腫瘍組織を用いてRNAシークエンスを実施した。パスウェイ解析では、PLD2-KOマウスではMSP-RON Signaling in Macrophages Pathway、S100 Family Signaling Pathwayが亢進しており、その発がん過程において腫瘍関連マクロファージ(TAM)や骨髄由来抑制細胞が関与している可能性が示唆された。皮下移植モデルにおける腫瘍組織では、PLD2-KOによりFACSでTAMの増加を認めた。さらにマウス骨髄由来マクロファージ(BMDM)を回収し、M-CSFおよびMB49の培地上清を添加によりBMDM-TAMを樹立した。PLD-2-KOマウスより作成したBMDM-TAMはPLD2-WTと比較して増殖能が亢進していることが明らかとなった。
    マウス膀胱がん細胞株MB49による皮下移植モデルにおいて、BBN膀胱発がんモデルと同様にPLD2-KOマウスでは腫瘍形成が促進されることが明らかとになった。BBN膀胱発がんモデルにおける16週時点の腫瘍組織を用いてRNAシークエンスを実施した。PLD2-WTマウスとPLD2-KOマウスにおける変動遺伝子を抽出し、パスウェイ解析を行ったところ、PLD2-KOマウスではMSP-RON Signaling in Macrophages Pathway、S100 Family Signaling Pathwayが亢進しており、その発がん過程において腫瘍関連マクロファージ(TAM)や骨髄由来抑制細胞(MDSC)が関与している可能性が示唆された。さらに、皮下移植モデルにおける腫瘍組織を用いてFACSでTAMとMDSCの評価を行った。PLD2-KOマウスでは、PLD2-WTマウスと比較して腫瘍内のTAMの増加を認めたが、MDSCは差を認めなかった。さらにマウス骨髄由来マクロファージ(BMDM)を回収し、M-CSFおよびMB49の培地上清を添加によりBMDM-TAMを樹立した。PLD-2-KOマウスより作成したBMDM-TAMはPLD2-WTと比較して増殖能が亢進していることが明らかとなった。
    BBN膀胱発がんモデルにおける膀胱組織を用いて免疫化学染色を行い、腫瘍内を構成する免疫細胞の評価を行い、PLD2-KOマウスにおけるがん微小免疫環境の全体像を把握する。併せて同組織で実施しているRNAシークエンスの結果から、デジタルサイトメトリーを行い、免疫化学染色の結果との比較を行う。また、皮下移植モデルにおける腫瘍組織からPLD2-WTとPLD2-KOのTAMを分離し、RNAシークエンスを行う。さらに、PLD2-WTとPLD2-KOマウスから骨髄由来マクロファージ(BMDM)から樹立したTAMを用いて、RNAシークエンスを行う。これらのトランスクリプトーム解析によりPLD2-WTとPLD2-KOのTAMとしての機能の差異を検討する。特にサイトカイン関連遺伝子の変化に着目し、RNAシークエンスの結果からin vitroでのサイトカイン分泌能の評価をELISA等で実施する予定である。

 

Teaching Experience (On-campus) 1

  1. 基本的臨床技能実習(導尿)

    2024

Teaching Experience (Off-campus) 2

  1. Pre-CC

    2019.4 - 2023.12 University of Tsukuba, School of Medicine)

  2. BPH, Prostate cancer

    2016.6 - 2023.12 University of Tsukuba, School of Medicine)